1. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
- Author
-
Rubinstein, Samuel M., Bhutani, Divaya, Lynch, Ryan C., Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A., Mishra, Sanjay, Mundt, Daniel P., Shah, Dimpy P., Sica, R. Alejandro, Stockerl-Goldstein, Keith E., Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E., Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A., Cogan, Jacob C., KC, Devendra, Friese, Christopher R., Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A., Joshi, Monika, Kasi, Anup, Klein, Elizabeth J., Koshkin, Vadim S., Kuderer, Nicole M., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H., McKay, Rana R., Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K., Olszewski, Adam J., Polimera, Hyma V., Portuguese, Andrew J., Puc, Matthew M., Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A., Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M., Zubiri, Leyre, Warner, Jeremy L., and Thompson, Michael A.
- Subjects
Research Briefs ,COVID-19 Testing ,Risk Factors ,SARS-CoV-2 ,Neoplasms ,COVID-19 ,Humans ,General Medicine ,Lymphatic Diseases - Abstract
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171
- Published
- 2022
- Full Text
- View/download PDF